BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 4, 2026
Home
»
Newsletters
» BioWorld
BioWorld
March 27, 2002
View Archived Issues
ISTA’s Stock Slides On Vitrase Missed Primary Endpoint
Wall Street did not look kindly on ISTA Pharmaceuticals’ failure to meet its primary endpoint in two pivotal Phase III studies of Vitrase, a single injection for treating vitreous hemorrhage. (BioWorld Today)
Read More
AVI Financing Garners $22M For Antisense, Cancer Vaccines
Read More
Huntington’s Disease Divulges Perplexities Of Its Horrendous Hallmarks, Inexorable Lethality
Read More
TKT’s Dynepo Gains Approval In Europe; Amgen Fight Goes On
Read More
Bush Unveils Planned NIH, Surgeon General Nominations
Read More
Other News To Note
Read More
